{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T09:08:55Z","timestamp":1754557735206,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T00:00:00Z","timestamp":1565395200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T00:00:00Z","timestamp":1565395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP17ck0106110"],"award-info":[{"award-number":["JP17ck0106110"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s12185-019-02714-x","type":"journal-article","created":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T12:02:43Z","timestamp":1565438563000},"page":"627-634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Bortezomib-containing therapy in Japanese children with relapsed acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9446-9568","authenticated-orcid":false,"given":"Daisuke","family":"Hasegawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Kumamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kikuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Kada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Iijima-Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko M.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keizo","family":"Horibe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chitose","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,10]]},"reference":[{"key":"2714_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s12185-013-1364-2","volume":"98","author":"K Horibe","year":"2013","unstructured":"Horibe K, Saito AM, Takimoto T, Tsuchida M, Manabe A, Shima M, et al. Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006\u20132010): based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol. 2013;98:74\u201388.","journal-title":"Int J Hematol"},{"key":"2714_CR2","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541\u201352.","journal-title":"N Engl J Med"},{"key":"2714_CR3","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/ped.12837","volume":"57","author":"H Goto","year":"2015","unstructured":"Goto H. Childhood relapsed acute lymphoblastic leukemia: biology and recent treatment progress. Pediatr Int. 2015;57:1059\u201366.","journal-title":"Pediatr Int"},{"key":"2714_CR4","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1182\/blood-2012-02-265884","volume":"120","author":"F Locatelli","year":"2012","unstructured":"Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood. 2012;120:2807\u201316.","journal-title":"Blood"},{"key":"2714_CR5","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","volume":"28","author":"G Tallen","year":"2010","unstructured":"Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol. 2010;28:2339\u201347.","journal-title":"J Clin Oncol"},{"key":"2714_CR6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/pbc.22456","volume":"55","author":"Y Messinger","year":"2010","unstructured":"Messinger Y, Gaynon P, Raetz E, Hutchinson R, Dubois S, Glade-Bender J, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010;55:254\u20139.","journal-title":"Pediatr Blood Cancer"},{"key":"2714_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2012-04-418640","volume":"120","author":"YH Messinger","year":"2012","unstructured":"Messinger YH, Gaynon PS, Sposto R, van der Giessen J, Eckroth E, Malvar J, et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: therapeutic advances in childhood leukemia and lymphoma (TACL) study. Blood. 2012;120:285\u201390.","journal-title":"Blood"},{"key":"2714_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s12185-017-2235-z","volume":"106","author":"A Iguchi","year":"2017","unstructured":"Iguchi A, Cho Y, Sugiyama M, Terashita Y, Ariga T, Hosoya Y, et al. Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia. Int J Hematol. 2017;106:291\u20138.","journal-title":"Int J Hematol"},{"key":"2714_CR9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.leu.2404586","volume":"21","author":"VH van der Velden","year":"2007","unstructured":"van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21:604\u201311.","journal-title":"Leukemia"},{"key":"2714_CR10","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","volume":"17","author":"JJ van Dongen","year":"2003","unstructured":"van Dongen JJ, Langerak AW, Br\u00fcggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257\u2013317.","journal-title":"Leukemia"},{"key":"2714_CR11","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/cas.12172","volume":"104","author":"Y Ogawa","year":"2013","unstructured":"Ogawa Y, Suzuki K, Sakai A, Evans PA, Hummel M, Lavender FL, et al. Phase I\/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma. Cancer Sci. 2013;104:912\u20139.","journal-title":"Cancer Sci"},{"key":"2714_CR12","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1158\/1078-0432.CCR-06-2173","volume":"13","author":"TM Horton","year":"2007","unstructured":"Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, Adamson PC, et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children\u2019s Oncology Group study. Clin Cancer Res. 2007;13:1516\u201322.","journal-title":"Clin Cancer Res"},{"key":"2714_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/bjh.14505","volume":"176","author":"A Bertaina","year":"2017","unstructured":"Bertaina A, Vinti L, Strocchio L, Gaspari S, Caruso R, Algeri M, et al. The combination of bortezomib with chemotherapy to treat relapsed\/refractory acute lymphoblastic leukaemia of childhood. Br J Haematol. 2017;176:629\u201336.","journal-title":"Br J Haematol"},{"key":"2714_CR14","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","volume":"24","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24:3113\u201320.","journal-title":"J Clin Oncol"},{"key":"2714_CR15","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1182\/blood-2005-11-4541","volume":"107","author":"S Miyakoshi","year":"2006","unstructured":"Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 2006;107:3492\u20134.","journal-title":"Blood"},{"key":"2714_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/cas.12335","volume":"105","author":"K Yoshizawa","year":"2014","unstructured":"Yoshizawa K, Mukai HY, Miyazawa M, Miyao M, Ogawa Y, Ohyashiki K, et al. Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization. Cancer Sci. 2014;105:195\u2013201.","journal-title":"Cancer Sci"},{"key":"2714_CR17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1349-7006.2007.00638.x","volume":"99","author":"Y Ogawa","year":"2008","unstructured":"Ogawa Y, Tobinai K, Ogura M, Ando K, Tsuchiya T, Kobayashi Y, et al. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Cancer Sci. 2008;99:140\u20134.","journal-title":"Cancer Sci"},{"key":"2714_CR18","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1200\/JCO.2012.48.5680","volume":"31","author":"C Eckert","year":"2013","unstructured":"Eckert C, Henze G, Seeger K, Hagedorn N, Mann G, Panzer-Gr\u00fcmayer R, et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol. 2013;31:2736\u201342.","journal-title":"J Clin Oncol"},{"key":"2714_CR19","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.3109\/10428194.2011.593271","volume":"52","author":"X Hu","year":"2011","unstructured":"Hu X, Xu J, Sun A, Shen Y, He G, Guo F. Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-\u03baB activity. Leuk Lymphoma. 2011;52:2393\u20135.","journal-title":"Leuk Lymphoma"},{"key":"2714_CR20","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjh.15919","volume":"186","author":"TM Horton","year":"2019","unstructured":"Horton TM, Whitlock JA, Lu X, O\u2019Brien MM, Borowitz MJ, Devidas M, et al. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children\u2019s Oncology Group. Br J Haematol. 2019;186:274\u201385.","journal-title":"Br J Haematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02714-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-019-02714-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02714-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T22:04:05Z","timestamp":1721599445000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-019-02714-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,10]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["2714"],"URL":"https:\/\/doi.org\/10.1007\/s12185-019-02714-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2019,8,10]]},"assertion":[{"value":"8 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}